Roche beefs up diagnostics with $100M BioImagene; Aspen posts 25 percent earnings hike;

@FiercePharma: Genzyme shareholder sues to stop Sanofi acquisition. Article | Follow @FiercePharma

> Roche has added to its portfolio of diagnostics products by acquiring U.S.-based BioImagene, which specializes in tissue-based cancer diagnostics, for $100 million. Article

> Africa's biggest generic drugmaker Aspen Pharmacare said full-year headline earnings per share likely rose by 25 percent boosted by its South African operations. Report

> Irish drug maker Warner Chilcott has completed a loan and a debt offering necessary to pay a special dividend of $8.50 per share that it announced last month. Story

> Sun Pharmaceutical Industries said it is planning to enter the Japanese generics market, with drugs aimed at treating chronic diseases. Story

> Novartis is seeking to use Swiss merger law to push through its buy of a minority stake in U.S. eyecare firm Alcon (ACL.N), which would give it full control of the group. Item

> British drugmaker AstraZeneca spent $740,000 in the second quarter lobbying the U.S. federal government, according to a recent disclosure form. News

> GlaxoSmithKline spent just over $1.2 million lobbying federal officials on patent laws and other issues during the second quarter, according to a recent disclosure form. Article

 @FierceBiotech:  Which biotechs are the least efficient? News | Follow @FierceBiotech

Biotech News

> Taligen gets $10M cash injection for rare disease platform. Item

> Hep E vaccine aces large late-stage study in China. Article

> U.S. biotech faces fierce international competition. Story

> EpiCept shares hammered after FDA rejects app, demands new trial. News

> Archimedes starts recruiting for new U.S. headquarters. Report

Biotech IT News

> Roche writes social media rules for employees. Item

> Top 10 list rejects cloud for clinical data. News

> UK study supports dose-response modeling. Story

> Google-like code aids drug development. Report

> NIH funds software-based brain plasticity trials. Article

> Cloud to host Saffron predictive analytics tool. News

And Finally... What happens to attention, memory and learning when we step away from our devices and rest our brains? Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…